HC016 cells modulate the inflammatory process by releasing specific enzymes and growth factors.
Additionally, cells show increased survival rates following implant due to an enhanced resistance against the cytotoxic environment in the injury site.
Clinical Phase I/II ongoing:
Phase I completed with 6 patients.
Phase IIa starts Q2 2019.
Co-development agreement with Ferrer.